1. Introduction {#s0005}
===============

In the absence of a vaccine the medical and scientific community is looking intensely at utilizing a pre or post exposure drug that could decrease viremia. The search for a medication that could reduce risk of serious disease, and ideally of any disease and of asymptomatic shedding of SARS-CoV2 is of urgent interest, particularly to decrease the risk to health care workers, first responders, and others with high risk of exposure to patients with COVID19. The prospect of protecting health-care workers against COVID-19 based on repurposing of existing pharmaceuticals is among one of the recent scientific debates \[[@bb0005],[@bb0010]\]. The value of hydroxychloroquine (HCQ) as a prophylactic needs careful documented, empirical research in this context \[[@bb0015]\]. In order to obtain strong clinical evidence, a large number of scientists and teams have launched prospective studies that were registered on [ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0015} over a short period of time. The detailed analysis of these studies, some of them already recruiting, will give an overall picture of HCQ use as a COVID-19 prophylaxis around the world. This will help to identify the gaps to be fulfilled with the idea of getting definitive evidence on the positioning of HCQ for COVID-19 prophylaxis in exposed health-care workers.

2. Material and methods {#s0010}
=======================

We performed a systematic review of all interventional studies registered in [ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0020} on the 27th of April under the disease "COVID" and "hydroxychloroquine prophylaxis" as other terms \[[@bb0020]\]. No other filter was used. Studies using hydroxychloroquine (HCQ) as treatment, studies that did not record details about HCQ regimen, as well as those using HCQ in combination with other drugs, were not included. [ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0025} is a Web-based resource maintained by the National Library of Medicine that provides patients, their family members, health care professionals, researchers, and the public with access to information on clinical studies. Information on [ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0030} is provided and updated by the sponsor or principal investigator of the clinical study.

Two independent authors (ALB, SP) performed the screening of the study record detail to assess eligibility. Data were extracted by Information collected included [ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0035} identifier, official title, recruitment status, starting and completion dates, estimated enrolment, allocation, location, intervention model, masking, and HCQ regimen. To ensure reproducibility and completeness of data extraction, an Excel spreadsheet (Microsoft Corp., Redmond, WA, USA) compiling all variables to be extracted was used. Disagreements over eligibility or data extraction were resolved by discussion. Data were centrally checked by an independent operator for completeness, plausibility, and integrity before synthesis.

3. Results {#s0015}
==========

All interventional clinical trials that studied the use of HCQ for COVID-19 prophylaxis were included in the qualitative analysis. Forty-one (*n* = 41) studies were identified through [ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0040} on the 27th of April ([Fig. 1](#f0005){ref-type="fig"}). After screening for eligibility record details of the selected studies, 31 studies were included in the qualitative analysis. Ten studies were not included: reasons for exclusion included the absence of details about HCQ regimen (*n* = 1), the use of HCQ as indication other than prophylaxis (*n* = 3), and the combination of HCQ to other drugs or vitamins (*n* = 6). The qualitative analysis focussed on HCQ drug regimens of the 31 included studies as recorded in [ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0045} from the 17th of March to the 24th of April. (See [Table 1](#t0005){ref-type="table"}.)Fig. 1PRISMA 2009 Flow Diagram.Fig. 1Table 1Description of interventional studies registered in ClinicalTrials.gov on the 27th of April under the disease "COVID" and "hydroxychloroquine prophylaxis".Table 1**NCTTitleStarting DateCompletion dateRecrutingLocationRandomizationMaskingPlaceboNb patientsNb in HCQ armDose D1**\
**mgDose per day mgNb daysDose per weekNb of weeks**4,308,668Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical TrialMarch 17, 2020April 21, 2020YesMinneapolis, Minnesota, USAYesQuadrupleYes30001500**14006005**mg**--**4,334,148Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine TrialApril 2020July 2020NoDuke University\
Durham, UKYesTripleYes15,0007500**120040030**mg**--**4,342,221Randomized Controlled Trial of Hydroxychloroquine Versus Placebo for the Treatment of Adult Patients With Acute Coronavirus Disease 2019 - COVID-19March 29, 2020March 2021YesUniversity Hospital Tuebingen, GermanyYesQuadrupleYes220110**8006007**mg**--**4,329,923Prevention And Treatment of COVID-19 With HydroxychloroquineApril 2020April 2021YesUniversity of Pennsylvania, USAYesTripleYes400200**60060060**mg**--**4,353,037PATCH 2 & 3: Prevention and Treatment of COVID-19 With Hydroxychloroquine) An Open Label Multi-arm Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19April 7, 2020April 2021YesProHealth New York, USAYesDoubleYes850210**60060060**mg**--**4,352,933ChemoPROphyLaxIs For covId-19 Infectious Disease (the PROLIFIC Trial)April 2020October 31, 2020NoCambridge University Hospitals NHS Foundation Trust, UKYesQuadrupleYes1000330**800 D1 & D220090or 400/wk after loading12**4,330,144Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-201/04/202030/03/2021NoGangnan severance hospital, Seoul, South KoreaYesSingleNo24861243**8004005**mg**--**4,318,444Hydroxychloroquine Post Exposure Prophylaxis (PEP) for Household Contacts of COVID-19 Patients: A NYC Community-Based Randomized Clinical TrialMarch 2020March 2021NoColumbia University Irving Medical Center New York, USAYesQuadrupleYes1600800**8004005**mg**--**4,342,156Safety And Efficacy Of Hydroxychloroquine As COVID-19 Prophylaxis For At-Risk PopulationApril 2020August 2020NoTan Tock Seng Hospital\
SingaporeYesNoneNo1200600**8004005**mg**--**4,304,053Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study)March 18, 2020June 15, 2020YesDepartament de Salut, Barcelona, SpainYesNoneNo30401520**8004005**mg**--**4,329,611A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Oral Hydroxychloroquine for the Treatment of SARS-CoV-2 Positive Patients for the Prevention of Severe COVID-19 Disease.April 13August 31, 2020YesUniversity of Calgary/Foothills Medical Centre, Calgary, Alberta, CanadaYesTripleYes1660550**8004005**mg**--**4,351,191Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 Coronavirus Infectious Disease 2019 Patients to RT- PCR-Negative as a Means to Reduce Hospitalization RateApril 15, 2020April 30, 2020NoMayo Hospital Lahore, PakistanYesQuadrupleYes400100**8004005**mg**--**4,303,507Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare SettingApril 2020April 2021NoUniversity of Oxford, UKYesDoubleYes40,00020,000**60020090**mg**--**4,354,870ff Label Study to Evaluate the Efficacy of HCQ for Pre-exposure Prophylaxis (PrEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers (HCWs) Who Are at High Risk of Occupational Exposure to SARS-CoV-2April 3, 2020August 1, 2020YesNYU Langone Health\
New York, New York, USANoNoneNo350300**60020090**mg**--**4,330,495Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and/or JAK Inhibitors in the Prevention of SARS-CoV-2 InfectionApril 6, 2020Nov 6, 2020NoInstituto de Investigación Marqués de Valdecilla, SpainYesDoubleYes800400**400400180**mg**--**4,352,946Protecting Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis: A Randomized, Placebo-controlled TrialApril 24June 24, 2020NoGeoSentinel FoundationYesQuadrupleYes374187**40040060**mg**--**4,328,285Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers: A Randomized Double-blind Placebo-controlled Clinical TrialApril 14, 2020Nov 30, 2020YesCHU de Saint-Etienne Institut Pasteur, FranceYesTripleYes1200300**40040060**mg**--**4,344,379Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the VirusApril 15, 2020July 31, 2020YesAssistance Publique - Hôpitaux de Paris, FranceYesDoubleYes900300**40040040**mg**--**4,331,834Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic: A Unicentric, Double-Blinded Randomized Controlled TrialApril 3, 2020Oct 3, 2020YesBarcelona Institute for Global Health, SpainYesQuadrupleYes440220**400400440024**4,328,961Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized StudyMarch 2020Sept 30, 2020YesUniversity of Washington New York University, USAYesDoubleAscorbic acid20001000**400 D1-D320014**mg**--**4,341,441Will Hydroxychloroquine Impede or Prevent COVID-19: WHIP COVID-19 StudyApril 7, 2020June 30, 2020YesDetroit, Michigan, USAYesTripleYes30001500**40020056Or 6.5** **mg/kg/week8**4,336,748Low-dose Hydroxychloroquine for Primary Prophylaxis Against SARS-CoV-2 in Health-care Workers - a Randomized, Double-blind, Controlled TrialApril 2020July 2020NoMedical University of Vienna, AustriaYesTripleYes440220**20020028**mg**--**4,318,015Chemoprophylaxis With Hydroxychloroquine in Healthcare Personnel in Contact With COVID-19 Patients: A Randomized Controlled TrialApril 14, 2020Dec 31, 2020YesNational Institute of Respiratory Diseases, MexicoYesQuadrupleYes400200**20020060**mg**--**4,334,928Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With PlaceboApril 15, 2020June 30, 2020NoHospital Universitario Ramón y Cajal, Madrid, Spain,YesDoubleYes40001000**20020084**mg**--**4,349,228Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health ProfessionalsApril15, 2020July 15, 2020NoHôpital Abderrahmane Mami-Ariana Tunis, TunisiaYesSingleYes530265**20020060**mg**--**4,328,467Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical TrialApril6, 2020August 2020YesMinneapolis, Minnesota, USAYesQuadrupleYes35001166**800--140012**4,328,467Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical TrialApril6, 2020August 2020YesMinneapolis, Minnesota, United States, USAYesQuadrupleYes35001166**800--180012**4,333,225A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk ExposuresApril 3, 2020July 30, 2020invitationBaylor University Medical Center Dallas, Texas, USANoNoneNo360360**800--14007**4,347,889Prophylactic Hydroxychloroquine vs Vitamin C in Healthcare Workers at Risk of COVID-19: A RCTApril 20Dec 30, 2020NoStony Brook University, New York USAYesSingleVitamin C1212606**800--140012**4,352,933ChemoPROphyLaxIs For covId-19 Infectious Disease (the PROLIFIC Trial)April 2020Oct 31, 2020NoCambridge University Hospitals NHS Foundation Trust, UKYesQuadrupleYes330**800 D1 & D220090or 400/wk after loading12**4,341,441Will Hydroxychloroquine Impede or Prevent COVID-19: WHIP COVID-19 StudyApril 7, 2020June 30, 2020YesDetroit, Michigan, USAYesTripleYes30001500**40020056Or 6.5** **mg/kg/week8**4,345,653Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare WorkersApril 14, 2020April 8, 2021YesHackensack Meridian Health - JFK Medical Center Edison, New Jersey, USANoNoneNo4545**400--14003**

Among the included studies, all but three were randomized and parallel and most of them (74%, 23/31) were double-blinded to quadruple-blinded studies. On the 27th of April, 55% (17/31) of them were recruiting. Estimated enrolment in HCQ arm was from 45 to 20.000 participants, with a median of 380 participants and a total of 45.728 persons receiving HCQ.

Regarding HCQ regimen, 61% (19/31) of the included studies used an HCQ loading dose, followed by daily (14/19) or weekly (5/19) doses. The range of the loading doses was from 400 to 1400 mg on day 1. The most common daily doses were 400 mg (12/31 (39%)) and 200 mg (9/31 (29%)); a 600 mg daily dose was less common and was recorded for only 13% (4/31) of the studies. The remaining six studies used weekly doses of 400 mg. Regarding the duration of prophylaxis, it was highly variable, ranging from 5 to 180 days (median = 40 days) for daily regimen, and 3 to 24 weeks for weekly regimen (median = 12 weeks). Of note, the most frequent prophylactic regimen (6/31 (19%)) was an HCQ loading dose of 800 mg on day 1, followed by HCQ 400 mg for four additional days. Among the studies (*n* = 5) that did not use a loading dose but a 400 mg daily dose, duration of prophylaxis was highly diverse from 4 to 180 days (median = 60). For the studies (*n* = 2) that reported a 200 mg daily dose, one study used a loading dose of 800 mg on day 1 and 2, followed by 90 days of 200 mg HCQ, and the other one used a loading dose of 400 mg from day 1 to 3, followed by 14 days of 200 mg HCQ.

4. Discussion {#s0020}
=============

More than 40 randomized clinical trials have been registered in less than 2 months from 13 different countries to answer the same question: should we used HCQ to protect health-care workers from the COVID-19 consequences? This very active recording in [ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0050} demonstrates the huge interest of the scientific community regarding this question. Indeed, the debate continues to rage regarding the use of HCQ for COVID-19 and we need to shed more light based on clinical evidence. At the present time, the debate is still a non-documented speculation that will be ended in the next few months.

The positive point regarding the high diversity of HCQ regimen among recorded clinical studies is that nearly all the possible regimens are under evaluation. The negative point of the high diversity in HCQ dosage and duration of prophylaxis could be that the conclusion of these different studies may be conflicting. Indeed, it would be surprising that a 200 mg daily dose during one month would have the same efficacy and the same ratio benefit/risk than a 600 mg daily dose during three months. As a consequence, the final analysis of these trials should be done through an extensive reading of the results in regards to the clinical design, rather than quickly glancing a 140 characters-based social media message announcing the failure or success of a drug against a disease.
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